Clinical Trial Update: A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer [Phase 4]

View source ↗

Summary

Phase 4 study evaluating two dosing regimens of cabozantinib (XL184) in progressive, metastatic medullary thyroid carcinoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Medullary Thyroid Cancer | Phase 4 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-02